Literature DB >> 25565637

Vasopressin decreases pulmonary-to-systemic vascular resistance ratio in a porcine model of severe hemorrhagic shock.

Joy Sarkar1, Patrick J Golden, Lauren N Kajiura, Lee-Ann M Murata, Catherine F T Uyehara.   

Abstract

Vasopressors are gaining renewed interest as treatment adjuncts in hemorrhagic shock. The ideal vasoconstrictor will increase systemic blood pressure without increasing pulmonary vascular resistance (PVR), which hinders pulmonary perfusion and exacerbates hypoxemia. However, the selectivity of pressors for pulmonary versus systemic vasoconstriction during hemorrhage has not been characterized. The purpose of this study was to test the hypothesis that vasopressin (VP) has distinct effects on pulmonary versus systemic hemodynamics, unlike the catecholamine vasopressors norepinephrine (NE) and phenylephrine (PE). Anesthetized and ventilated pigs were assigned to resuscitation with saline only (n = 7) or saline with VP (n = 6), NE (n = 6), or PE (n = 6). Animals were hemorrhaged to a target volume of 30 mL/kg and a mean arterial pressure of 35 mmHg. One hour after the start of hemorrhage, animals were resuscitated with saline up to one shed blood volume, followed by either additional saline or a vasopressor. Hemodynamics and oxygenation were measured hourly for 4 h after the start of hemorrhage. Vasopressin increased systemic vascular resistance (SVR) while sparing the pulmonary vasculature, leading to a 45% decrease in the PVR/SVR ratio compared with treatment with PE. Conversely, NE induced pulmonary hypertension and led to an increased PVR/SVR ratio associated with decreased oxygen saturation. Phenylephrine and crystalloid had no significant effect on the PVR/SVR ratio. Sparing of pulmonary vasoconstriction occurs only with VP, not with administration of crystalloid or catecholamine pressors. The ability of VP to maintain blood oxygenation indicates that VP may prevent hypoxemia in the management of hemorrhagic shock.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25565637     DOI: 10.1097/SHK.0000000000000325

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

1.  Vasopressin infusion in COVID-19 critical illness is not associated with impaired viral clearance: a pilot study.

Authors:  Daniel E Leisman; Arnav Mehta; Yijia Li; Kyle R Kays; Jonathan Z Li; Michael R Filbin; Marcia B Goldberg
Journal:  Br J Anaesth       Date:  2021-07-20       Impact factor: 11.719

2.  Effect of arginine vasopressin on systemic and pulmonary arterial pressure in a patient with pulmonary hypertension secondary to pulmonary emphysema: a case report.

Authors:  Toshiyuki Mizota; Kohei Fujiwara; Miho Hamada; Shino Matsukawa; Hajime Segawa
Journal:  JA Clin Rep       Date:  2017-01-04

3.  ECMO with vasopressor use during early endotoxic shock: Can it improve circulatory support and regional microcirculatory blood flow?

Authors:  Thornton S Mu; Amy M Becker; Aaron J Clark; Sherreen G Batts; Lee-Ann M Murata; Catherine F T Uyehara
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

4.  Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension.

Authors:  Marius M Hoeper; Raymond L Benza; Paul Corris; Marc de Perrot; Elie Fadel; Anne M Keogh; Christian Kühn; Laurent Savale; Walter Klepetko
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 5.  Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure.

Authors:  Angel Coz Yataco; Melina Aguinaga Meza; Ketan P Buch; Margaret A Disselkamp
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 6.  Pulmonary Artery Thrombosis: A Diagnosis That Strives for Its Independence.

Authors:  Olga Porembskaya; Yana Toropova; Vladimir Tomson; Kirill Lobastov; Leonid Laberko; Viacheslav Kravchuk; Sergey Saiganov; Alexander Brill
Journal:  Int J Mol Sci       Date:  2020-07-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.